<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00339183</url>
  </required_header>
  <id_info>
    <org_study_id>20050181</org_study_id>
    <nct_id>NCT00339183</nct_id>
  </id_info>
  <brief_title>Comparison of Treatment Effect of Chemotherapy With Panitumumab to Chemotherapy Alone</brief_title>
  <official_title>A Randomized, Multicenter Phase 3 Study to Compare the Efficacy of Panitumumab in Combination With Chemotherapy to the Efficacy of Chemotherapy Alone in Patients With Previously Treated Metastatic Colorectal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Amgen</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Amgen</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the treatment effect of panitumumab plus FOLFIRI
      compared to FOLFIRI alone as second line therapy for metastatic colorectal cancer.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2006</start_date>
  <completion_date type="Actual">November 2010</completion_date>
  <primary_completion_date type="Actual">April 2009</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-free Survival (PFS)</measure>
    <time_frame>From randomization until the data cut-off date of 8 April 2008. Maximum follow-up time was 17 months.</time_frame>
    <description>Progression-free survival was defined as the time from randomization to first disease progression per modified Response Evaluation Criteria in Solid Tumors (RECIST) criteria or death, based on independent central radiological assessment. Participants who were alive but did not meet criteria for progression by the data cutoff date were censored at their last evaluable disease assessment date.
Progressive disease is defined as a ≥ 20% increase in the size of target lesions or unequivocal progression of existing non-target lesions or any new lesions.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>From randomization until the data cut-off date of 30 April 2009. Maximum follow-up time was 33 months</time_frame>
    <description>Overall survival was defined as the time from randomization to the date of death. Participants who had not died by the analysis data cutoff date had their time of death censored at their last contact date.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With an Objective Response</measure>
    <time_frame>Every 8 weeks until disease progression up to the data cut-off date of 30 April 2009. Maximum time on follow-up was 33 months.</time_frame>
    <description>Participants were evaluated for tumor response per the modified Response Evaluation Criteria in Solid Tumors (RECIST) criteria every 8 weeks until disease progression. Objective response was defined as the incidence of either a confirmed complete or partial response (CR or PR) while on study, as determined by blinded independent central review and confirmed no less than 4-weeks after the criteria for response are first met. CR: Disappearance of all target and non-target lesions and no new lesions. PR: At least a 30% decrease in the sum of the longest diameter of target lesions and no progression of non-target or no new lesions, or, disappearance of all target lesions and the persistence of ≥ 1 non-target lesion not qualifying for either CR or progressive disease. Participants without a post-baseline assessment were considered non-responders.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Disease Progression</measure>
    <time_frame>From randomization until the data cut-off date of 30 April 2009. Maximum follow-up time was 33 months</time_frame>
    <description>Time to progression was defined as the time from the randomization date to the date of first observed disease progression per the modified RECIST criteria. Participants not meeting these criteria by the analysis data cutoff date were censored at their last evaluable disease assessment date.
Progressive disease is defined as a ≥ 20% increase in the size of target lesions or unequivocal progression of existing non-target lesions or any new lesions.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response</measure>
    <time_frame>From randomization until the data cut-off date of 30 April 2009. Maximum follow-up time was 33 months</time_frame>
    <description>Calculated only for those participants with an objective response as the time from the first objective response (subsequently confirmed within no less than 4 weeks) to first observed disease progression per modified-RECIST criteria. Participants not meeting these criteria by the analysis data cutoff date were censored at their last evaluable disease assessment date.
Progressive disease is defined as a ≥ 20% increase in the size of target lesions or unequivocal progression of existing non-target lesions or any new lesions.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Adverse Events (AEs)</measure>
    <time_frame>From randomization until the data cut-off date of 30 April 2009. Maximum follow-up time was 33 months.</time_frame>
    <description>A serious adverse event (SAE) is defined by regulatory authorities as one that • is fatal • is life threatening (places the subject at immediate risk of death) • requires in-patient hospitalization or prolongation of existing hospitalization • results in persistent or significant disability/incapacity • is a congenital anomaly/birth defect • other significant medical hazard. The relationship of the adverse event to the study treatment was assessed by the Investigator by means of the question: &quot;Is there a reasonable possibility that the event may have been caused by the study treatment?&quot;</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">1186</enrollment>
  <condition>Metastatic Colorectal Cancer</condition>
  <arm_group>
    <arm_group_label>Panitumumab Plus FOLFIRI</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received panitumumab as an intravenous (IV) infusion at a dose of 6 mg/kg plus a standard chemotherapy regimen (FOLFIRI) consisting of 5-fluorouracil (5-FU), leucovorin and irinotecan. Treatment was administered in cycles every two weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>FOLFIRI Alone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants received standard chemotherapy regimen (FOLFIRI) consisting of 5-FU, leucovorin and irinotecan. Treatment is administered in cycles every two weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Panitumumab</intervention_name>
    <description>Panitumumab was administered by IV infusion on Day 1 of each 14-day cycle, just before administration of FOLFIRI chemotherapy.</description>
    <arm_group_label>Panitumumab Plus FOLFIRI</arm_group_label>
    <other_name>Vectibix®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>FOLFIRI</intervention_name>
    <description>FOLFIRI chemotherapy was initiated on Day 1 of each treatment cycle at the following starting doses: irinotecan 180 mg/m^2, leucovorin 400 mg/m^2 racemate (or 200 mg/m^2 I-leucovorin), 5-FU bolus 400 mg/m^2, 5-FU infusion 2400 mg/m^2.</description>
    <arm_group_label>Panitumumab Plus FOLFIRI</arm_group_label>
    <arm_group_label>FOLFIRI Alone</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Man or woman at least 18 years old

          -  Diagnosis of metastatic colorectal cancer (mCRC)

          -  One and only one chemotherapy regimen for mCRC consisting of first-line 5-FU -based
             chemotherapy

          -  Radiologically documented disease progression per modified Response Evaluation
             Criteria in Solid Tumors (RECIST) criteria during treatment or within 6 months of last
             dose of first-line chemotherapy

          -  At least 1 uni-dimensionally measurable lesion of at least 20 mm per modified RECIST

          -  Eastern Cooperative Oncology Group (ECOG) status of 0, 1, or 2

          -  Paraffin-embedded tumor tissue from the primary tumor or metastasis available for
             central analyses

          -  Adequate hematologic, renal, and hepatic functions

          -  Negative pregnancy test within 72 hours of enrollment

          -  Other protocol-specified criteria may apply

        Exclusion Criteria:

          -  History of or known presence of central nervous system (CNS) metastases

          -  History of another primary cancer within 5 years of randomization

          -  Prior irinotecan therapy

          -  Prior anti-epidermal growth factor receptor (EGFr) antibody therapy or treatment with
             small molecule EGFr inhibitors

          -  Any investigational agent or therapy within 30 days before randomization

          -  Known allergy or hypersensitivity to irinotecan, 5-FU or leucovorin

          -  History of interstitial lung disease or evidence of interstitial lung disease on
             baseline chest computed tomography (CT) scan

          -  Active inflammatory bowel disease or other bowel disease causing chronic diarrhea

          -  Known positive tests for human immunodefiency virus (HIV), hepatitis C viris (HCV),
             acute or chronic active hepatitis B virus (HBV)

          -  Major surgery within 28 days of randomization or minor surgical procedure within 14
             days of randomization

          -  Pregnant or breast-feeding

          -  Man or woman of child-bearing potential not consenting to use adequate contraceptive
             methods or abstinence during the course of the study and for 6 months after last study
             drug administration (women) or 1 month after last study drug administration (men)

          -  Other protocol-specified criteria may apply
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>MD</last_name>
    <role>Study Director</role>
    <affiliation>Amgen</affiliation>
  </overall_official>
  <removed_countries>
    <country>Australia</country>
    <country>Austria</country>
    <country>Belgium</country>
    <country>Bulgaria</country>
    <country>Czech Republic</country>
    <country>Finland</country>
    <country>France</country>
    <country>Germany</country>
    <country>Ireland</country>
    <country>Italy</country>
    <country>Japan</country>
    <country>Lithuania</country>
    <country>Netherlands</country>
    <country>Norway</country>
    <country>Poland</country>
    <country>Portugal</country>
    <country>Romania</country>
    <country>Russian Federation</country>
    <country>Slovakia</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>Switzerland</country>
    <country>Ukraine</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </removed_countries>
  <link>
    <url>http://www.amgentrials.com</url>
    <description>AmgenTrials clinical trials website</description>
  </link>
  <reference>
    <citation>Peeters M, Price TJ, Cervantes A, Sobrero AF, Ducreux M, Hotko Y, André T, Chan E, Lordick F, Punt CJ, Strickland AH, Wilson G, Ciuleanu TE, Roman L, Van Cutsem E, Tian Y, Sidhu R. Final results from a randomized phase 3 study of FOLFIRI {+/-} panitumumab for second-line treatment of metastatic colorectal cancer. Ann Oncol. 2014 Jan;25(1):107-16. doi: 10.1093/annonc/mdt523. Erratum in: Ann Oncol. 2014 Mar;25(3):757.</citation>
    <PMID>24356622</PMID>
  </reference>
  <reference>
    <citation>Peeters M, Price TJ, Cervantes A, Sobrero AF, Ducreux M, Hotko Y, André T, Chan E, Lordick F, Punt CJ, Strickland AH, Wilson G, Ciuleanu TE, Roman L, Van Cutsem E, Tzekova V, Collins S, Oliner KS, Rong A, Gansert J. Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer. J Clin Oncol. 2010 Nov 1;28(31):4706-13. doi: 10.1200/JCO.2009.27.6055. Epub 2010 Oct 4.</citation>
    <PMID>20921462</PMID>
  </reference>
  <reference>
    <citation>Author and team decided to wait for CALGB RAS data presented Sept 29 at ESMO.</citation>
  </reference>
  <verification_date>February 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 16, 2006</study_first_submitted>
  <study_first_submitted_qc>June 16, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 20, 2006</study_first_posted>
  <results_first_submitted>April 3, 2014</results_first_submitted>
  <results_first_submitted_qc>April 3, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 6, 2014</results_first_posted>
  <disposition_first_submitted>July 20, 2010</disposition_first_submitted>
  <disposition_first_submitted_qc>July 20, 2010</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">July 22, 2010</disposition_first_posted>
  <last_update_submitted>February 7, 2017</last_update_submitted>
  <last_update_submitted_qc>February 7, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 9, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Oncology</keyword>
  <keyword>Cancer</keyword>
  <keyword>Metastatic Colorectal Cancer</keyword>
  <keyword>EGFr</keyword>
  <keyword>Panitumumab</keyword>
  <keyword>Clinical Trial</keyword>
  <keyword>Amgen</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Irinotecan</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>First patient enrolled 30 June 2006; Last patient enrolled 13 March 2008.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Panitumumab Plus FOLFIRI</title>
          <description>Participants were randomized to 6 mg/kg panitumumab intravenous infusion plus a standard chemotherapy regimen (FOLFIRI) consisting of 5-FU, leucovorin and irinotecan. Treatment was administered in cycles every two weeks.</description>
        </group>
        <group group_id="P2">
          <title>FOLFIRI Alone</title>
          <description>Participants were randomized to receive a standard chemotherapy regimen (FOLFIRI) consisting of 5-FU, leucovorin and irinotecan. Treatment was administered in cycles every two weeks.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="591"/>
                <participants group_id="P2" count="595"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received Study Drug</title>
              <participants_list>
                <participants group_id="P1" count="588">Includes one participant who received FOLFIRI Alone</participants>
                <participants group_id="P2" count="593"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="470">Indicates participants who had completed the safety visit 30 days after last dose or had died</participants>
                <participants group_id="P2" count="490">Indicates participants who had completed the safety visit 30 days after last dose or had died</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="121"/>
                <participants group_id="P2" count="105"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="19"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
                <participants group_id="P2" count="17"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol-specified criteria</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Missing reason</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="46"/>
                <participants group_id="P2" count="40"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Ongoing</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="13"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Panitumumab Plus FOLFIRI</title>
          <description>Participants were randomized to 6 mg/kg panitumumab intravenous infusion plus a standard chemotherapy regimen (FOLFIRI) consisting of 5-FU, leucovorin and irinotecan. Treatment was administered in cycles every two weeks.</description>
        </group>
        <group group_id="B2">
          <title>FOLFIRI Alone</title>
          <description>Participants were randomized to receive a standard chemotherapy regimen (FOLFIRI) consisting of 5-FU, leucovorin and irinotecan. Treatment was administered in cycles every two weeks.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="591"/>
            <count group_id="B2" value="595"/>
            <count group_id="B3" value="1186"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="60.2" spread="10.5"/>
                    <measurement group_id="B2" value="60.9" spread="10.6"/>
                    <measurement group_id="B3" value="60.6" spread="10.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="245"/>
                    <measurement group_id="B2" value="219"/>
                    <measurement group_id="B3" value="464"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="346"/>
                    <measurement group_id="B2" value="376"/>
                    <measurement group_id="B3" value="722"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>White or Caucasian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="568"/>
                    <measurement group_id="B2" value="569"/>
                    <measurement group_id="B3" value="1137"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Japanese</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or Other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Aborigine</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>KRAS Status</title>
          <description>KRAS, the human homolog of the Kirsten rat sarcoma-2 virus oncogene</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Wild-type KRAS</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="303"/>
                    <measurement group_id="B2" value="294"/>
                    <measurement group_id="B3" value="597"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mutant KRAS</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="238"/>
                    <measurement group_id="B2" value="248"/>
                    <measurement group_id="B3" value="486"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unevaluable KRAS</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="50"/>
                    <measurement group_id="B2" value="53"/>
                    <measurement group_id="B3" value="103"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Prior Oxaliplatin Exposure for mCRC</title>
          <description>mCRC: metastatic colorectal cancer</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="179"/>
                    <measurement group_id="B2" value="182"/>
                    <measurement group_id="B3" value="361"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="412"/>
                    <measurement group_id="B2" value="413"/>
                    <measurement group_id="B3" value="825"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Prior Bevacizumab Exposure for mCRC</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="480"/>
                    <measurement group_id="B2" value="483"/>
                    <measurement group_id="B3" value="963"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="111"/>
                    <measurement group_id="B2" value="112"/>
                    <measurement group_id="B3" value="223"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Eastern Cooperative Oncology Group (ECOG) Performance Status</title>
          <description>Grade 0: Fully active, able to carry on all pre-disease performance without restriction; Grade 1: Restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature; Grade 2: Ambulatory and capable of all self-care but unable to carry out any work activities. Up and about &gt; 50% of waking hours; Grade 3: Capable of only limited self care, confined to a bed or chair &gt; 50% of waking hours; Grade 4: Completely disabled. Cannot carry on any self-care. Totally confined to bed or chair; Grade 5: Dead</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Grade 0 or 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="564"/>
                    <measurement group_id="B2" value="565"/>
                    <measurement group_id="B3" value="1129"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                    <measurement group_id="B2" value="30"/>
                    <measurement group_id="B3" value="57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Progression-free Survival (PFS)</title>
        <description>Progression-free survival was defined as the time from randomization to first disease progression per modified Response Evaluation Criteria in Solid Tumors (RECIST) criteria or death, based on independent central radiological assessment. Participants who were alive but did not meet criteria for progression by the data cutoff date were censored at their last evaluable disease assessment date.
Progressive disease is defined as a ≥ 20% increase in the size of target lesions or unequivocal progression of existing non-target lesions or any new lesions.</description>
        <time_frame>From randomization until the data cut-off date of 8 April 2008. Maximum follow-up time was 17 months.</time_frame>
        <population>KRAS Efficacy Analysis Set (participants for whom KRAS status was assessed)</population>
        <group_list>
          <group group_id="O1">
            <title>Wild-type KRAS - Panitumumab Plus FOLFIRI</title>
            <description>Participants with wild-type KRAS were randomized to 6 mg/kg panitumumab plus FOLFIRI chemotherapy regimen administered in cycles every two weeks.</description>
          </group>
          <group group_id="O2">
            <title>Wild-type KRAS - FOLFIRI Alone</title>
            <description>Participants with wild-type KRAS were randomized to FOLFIRI chemotherapy regimen administered in cycles every two weeks.</description>
          </group>
          <group group_id="O3">
            <title>Mutant KRAS - Panitumumab Plus FOLFIRI</title>
            <description>Participants with mutant KRAS were randomized to 6 mg/kg panitumumab plus FOLFIRI chemotherapy regimen administered in cycles every two weeks.</description>
          </group>
          <group group_id="O4">
            <title>Mutant KRAS - FOLFIRI Alone</title>
            <description>Participants with mutant KRAS were randomized to FOLFIRI chemotherapy regimen administered in cycles every two weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Progression-free Survival (PFS)</title>
          <description>Progression-free survival was defined as the time from randomization to first disease progression per modified Response Evaluation Criteria in Solid Tumors (RECIST) criteria or death, based on independent central radiological assessment. Participants who were alive but did not meet criteria for progression by the data cutoff date were censored at their last evaluable disease assessment date.
Progressive disease is defined as a ≥ 20% increase in the size of target lesions or unequivocal progression of existing non-target lesions or any new lesions.</description>
          <population>KRAS Efficacy Analysis Set (participants for whom KRAS status was assessed)</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="303"/>
                <count group_id="O2" value="294"/>
                <count group_id="O3" value="238"/>
                <count group_id="O4" value="248"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.9" lower_limit="5.5" upper_limit="6.7"/>
                    <measurement group_id="O2" value="3.9" lower_limit="3.7" upper_limit="5.3"/>
                    <measurement group_id="O3" value="5.0" lower_limit="3.8" upper_limit="5.6"/>
                    <measurement group_id="O4" value="4.9" lower_limit="3.6" upper_limit="5.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>An overall 5% significance level was used to compare treatments with respect to both overall survival (OS) and PFS. A 4% and 1% level (2-sided) was used to independently test OS and PFS, respectively.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0036</p_value>
            <method>Stratified log-rank test</method>
            <method_desc>P-value based on a 2-sided log-rank test stratified by ECOG (0 or 1 vs. 2), prior bevacizumab exposure, and prior oxaliplatin exposure (yes or no).</method_desc>
            <param_type>Normal score</param_type>
            <param_value>-2.91</param_value>
            <estimate_desc>A normal score &lt;0 indicates fewer than expected events for the Panitumumab plus FOLFIRI arm and therefore a longer progression-free survival time.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>PFS in the Mutant Efficacy Analysis Set was compared at a 1% level conditional upon first demonstrating a significant difference in PFS in the Wild-type KRAS Efficacy Analysis Set.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1448</p_value>
            <method>Stratified log-rank test</method>
            <method_desc>P-value based on a 2-sided log-rank test stratified by ECOG (0 or 1 vs. 2), prior bevacizumab exposure and prior oxaliplatin exposure (yes or no).</method_desc>
            <param_type>Normal score</param_type>
            <param_value>-1.46</param_value>
            <estimate_desc>A normal score &lt;0 indicates fewer than expected events for the Panitumumab plus FOLFIRI arm and therefore a longer progression-free survival time.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Overall Survival</title>
        <description>Overall survival was defined as the time from randomization to the date of death. Participants who had not died by the analysis data cutoff date had their time of death censored at their last contact date.</description>
        <time_frame>From randomization until the data cut-off date of 30 April 2009. Maximum follow-up time was 33 months</time_frame>
        <population>KRAS Efficacy Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>Wild-type KRAS - Panitumumab Plus FOLFIRI</title>
            <description>Participants with wild-type KRAS were randomized to 6 mg/kg panitumumab plus FOLFIRI chemotherapy regimen administered in cycles every two weeks.</description>
          </group>
          <group group_id="O2">
            <title>Wild-type KRAS - FOLFIRI Alone</title>
            <description>Participants with wild-type KRAS were randomized to FOLFIRI chemotherapy regimen administered in cycles every two weeks.</description>
          </group>
          <group group_id="O3">
            <title>Mutant KRAS - Panitumumab Plus FOLFIRI</title>
            <description>Participants with mutant KRAS were randomized to 6 mg/kg panitumumab plus FOLFIRI chemotherapy regimen administered in cycles every two weeks.</description>
          </group>
          <group group_id="O4">
            <title>Mutant KRAS - FOLFIRI Alone</title>
            <description>Participants with mutant KRAS were randomized to FOLFIRI chemotherapy regimen administered in cycles every two weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival</title>
          <description>Overall survival was defined as the time from randomization to the date of death. Participants who had not died by the analysis data cutoff date had their time of death censored at their last contact date.</description>
          <population>KRAS Efficacy Analysis Set</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="303"/>
                <count group_id="O2" value="294"/>
                <count group_id="O3" value="238"/>
                <count group_id="O4" value="248"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.5" lower_limit="13.0" upper_limit="16.0"/>
                    <measurement group_id="O2" value="12.5" lower_limit="11.2" upper_limit="14.2"/>
                    <measurement group_id="O3" value="11.8" lower_limit="10.4" upper_limit="13.3"/>
                    <measurement group_id="O4" value="11.1" lower_limit="10.3" upper_limit="12.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>An overall 5% significance level was used to compare treatments with respect to both overall survival (OS) and PFS. A 4% and 1% level (2-sided) was used to independently test OS and PFS, respectively.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1154</p_value>
            <method>Stratified log-rank test</method>
            <method_desc>P-value based on a 2-sided log-rank test stratified by ECOG (0 or 1 vs. 2), prior bevacizumab exposure, and prior oxaliplatin exposure (yes or no).</method_desc>
            <param_type>Normal score</param_type>
            <param_value>-1.57</param_value>
            <estimate_desc>A normal score &lt;0 indicates fewer than expected events for the Panitumumab plus FOLFIRI arm and therefore a longer overall survival time.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>The treatment effect on OS in the Mutant KRAS Efficacy Analysis Set was compared at the 4% level conditional on first demonstrating a significant OS treatment effect in the Wild-type KRAS Efficacy Analysis Set.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.5503</p_value>
            <method>Stratified log-rank test</method>
            <method_desc>P-value based on a 2-sided log-rank test stratified by ECOG (0 or 1 vs. 2), prior bevacizumab exposure, and prior oxaliplatin exposure (yes or no).</method_desc>
            <param_type>Normal score</param_type>
            <param_value>-0.60</param_value>
            <estimate_desc>A normal score &lt;0 indicates fewer than expected events for the Panitumumab plus FOLFIRI arm and therefore a longer overall survival time.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With an Objective Response</title>
        <description>Participants were evaluated for tumor response per the modified Response Evaluation Criteria in Solid Tumors (RECIST) criteria every 8 weeks until disease progression. Objective response was defined as the incidence of either a confirmed complete or partial response (CR or PR) while on study, as determined by blinded independent central review and confirmed no less than 4-weeks after the criteria for response are first met. CR: Disappearance of all target and non-target lesions and no new lesions. PR: At least a 30% decrease in the sum of the longest diameter of target lesions and no progression of non-target or no new lesions, or, disappearance of all target lesions and the persistence of ≥ 1 non-target lesion not qualifying for either CR or progressive disease. Participants without a post-baseline assessment were considered non-responders.</description>
        <time_frame>Every 8 weeks until disease progression up to the data cut-off date of 30 April 2009. Maximum time on follow-up was 33 months.</time_frame>
        <population>KRAS Central Tumor Response Analysis Set: subset of participants with at least one uni-dimensionally measurable lesion per the modified RECIST criteria per blinded central radiology review for whom KRAS was assessed.</population>
        <group_list>
          <group group_id="O1">
            <title>Wild-type KRAS - Panitumumab Plus FOLFIRI</title>
            <description>Participants with wild-type KRAS were randomized to 6 mg/kg panitumumab plus FOLFIRI chemotherapy regimen administered in cycles every two weeks.</description>
          </group>
          <group group_id="O2">
            <title>Wild-type KRAS - FOLFIRI Alone</title>
            <description>Participants with wild-type KRAS were randomized to FOLFIRI chemotherapy regimen administered in cycles every two weeks.</description>
          </group>
          <group group_id="O3">
            <title>Mutant KRAS - Panitumumab Plus FOLFIRI</title>
            <description>Participants with mutant KRAS were randomized to 6 mg/kg panitumumab plus FOLFIRI chemotherapy regimen administered in cycles every two weeks.</description>
          </group>
          <group group_id="O4">
            <title>Mutant KRAS - FOLFIRI Alone</title>
            <description>Participants with mutant KRAS were randomized to FOLFIRI chemotherapy regimen administered in cycles every two weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With an Objective Response</title>
          <description>Participants were evaluated for tumor response per the modified Response Evaluation Criteria in Solid Tumors (RECIST) criteria every 8 weeks until disease progression. Objective response was defined as the incidence of either a confirmed complete or partial response (CR or PR) while on study, as determined by blinded independent central review and confirmed no less than 4-weeks after the criteria for response are first met. CR: Disappearance of all target and non-target lesions and no new lesions. PR: At least a 30% decrease in the sum of the longest diameter of target lesions and no progression of non-target or no new lesions, or, disappearance of all target lesions and the persistence of ≥ 1 non-target lesion not qualifying for either CR or progressive disease. Participants without a post-baseline assessment were considered non-responders.</description>
          <population>KRAS Central Tumor Response Analysis Set: subset of participants with at least one uni-dimensionally measurable lesion per the modified RECIST criteria per blinded central radiology review for whom KRAS was assessed.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="297"/>
                <count group_id="O2" value="285"/>
                <count group_id="O3" value="232"/>
                <count group_id="O4" value="237"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.35" lower_limit="29.92" upper_limit="41.08"/>
                    <measurement group_id="O2" value="9.82" lower_limit="6.63" upper_limit="13.89"/>
                    <measurement group_id="O3" value="13.36" lower_limit="9.26" upper_limit="18.43"/>
                    <measurement group_id="O4" value="13.92" lower_limit="9.78" upper_limit="19.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Stratified exact test</method>
            <method_desc>Adjusted for ECOG score, prior bevacizumab exposure, prior oxaliplatin exposure.</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>5.33</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>3.21</ci_lower_limit>
            <ci_upper_limit>8.60</ci_upper_limit>
            <estimate_desc>The odds ratio is defined as the odds of having an objective response in the panitumumab plus arm relative to the odds on the FOLFIRI alone arm.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>1.0000</p_value>
            <method>Stratified exact test</method>
            <method_desc>Adjusted for ECOG score, prior bevacizumab exposure, prior oxaliplatin exposure.</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.00</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.56</ci_lower_limit>
            <ci_upper_limit>1.76</ci_upper_limit>
            <estimate_desc>The odds ratio is defined as the odds of having an objective response in the panitumumab plus arm relative to the odds on the FOLFIRI alone arm.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Disease Progression</title>
        <description>Time to progression was defined as the time from the randomization date to the date of first observed disease progression per the modified RECIST criteria. Participants not meeting these criteria by the analysis data cutoff date were censored at their last evaluable disease assessment date.
Progressive disease is defined as a ≥ 20% increase in the size of target lesions or unequivocal progression of existing non-target lesions or any new lesions.</description>
        <time_frame>From randomization until the data cut-off date of 30 April 2009. Maximum follow-up time was 33 months</time_frame>
        <population>KRAS Efficacy Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>Wild-type KRAS - Panitumumab Plus FOLFIRI</title>
            <description>Participants with wild-type KRAS were randomized to 6 mg/kg panitumumab plus FOLFIRI chemotherapy regimen administered in cycles every two weeks.</description>
          </group>
          <group group_id="O2">
            <title>Wild-type KRAS - FOLFIRI Alone</title>
            <description>Participants with wild-type KRAS were randomized to FOLFIRI chemotherapy regimen administered in cycles every two weeks.</description>
          </group>
          <group group_id="O3">
            <title>Mutant KRAS - Panitumumab Plus FOLFIRI</title>
            <description>Participants with mutant KRAS were randomized to 6 mg/kg panitumumab plus FOLFIRI chemotherapy regimen administered in cycles every two weeks.</description>
          </group>
          <group group_id="O4">
            <title>Mutant KRAS - FOLFIRI Alone</title>
            <description>Participants with mutant KRAS were randomized to FOLFIRI chemotherapy regimen administered in cycles every two weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Disease Progression</title>
          <description>Time to progression was defined as the time from the randomization date to the date of first observed disease progression per the modified RECIST criteria. Participants not meeting these criteria by the analysis data cutoff date were censored at their last evaluable disease assessment date.
Progressive disease is defined as a ≥ 20% increase in the size of target lesions or unequivocal progression of existing non-target lesions or any new lesions.</description>
          <population>KRAS Efficacy Analysis Set</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="303"/>
                <count group_id="O2" value="294"/>
                <count group_id="O3" value="238"/>
                <count group_id="O4" value="248"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.3" lower_limit="5.9" upper_limit="7.5"/>
                    <measurement group_id="O2" value="5.3" lower_limit="3.9" upper_limit="5.7"/>
                    <measurement group_id="O3" value="5.5" lower_limit="4.5" upper_limit="5.7"/>
                    <measurement group_id="O4" value="5.5" lower_limit="4.2" upper_limit="5.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Duration of Response</title>
        <description>Calculated only for those participants with an objective response as the time from the first objective response (subsequently confirmed within no less than 4 weeks) to first observed disease progression per modified-RECIST criteria. Participants not meeting these criteria by the analysis data cutoff date were censored at their last evaluable disease assessment date.
Progressive disease is defined as a ≥ 20% increase in the size of target lesions or unequivocal progression of existing non-target lesions or any new lesions.</description>
        <time_frame>From randomization until the data cut-off date of 30 April 2009. Maximum follow-up time was 33 months</time_frame>
        <population>KRAS Central Tumor Response Analysis Set: Responders</population>
        <group_list>
          <group group_id="O1">
            <title>Wild-type KRAS - Panitumumab Plus FOLFIRI</title>
            <description>Participants with wild-type KRAS were randomized to 6 mg/kg panitumumab plus FOLFIRI chemotherapy regimen administered in cycles every two weeks.</description>
          </group>
          <group group_id="O2">
            <title>Wild-type KRAS - FOLFIRI Alone</title>
            <description>Participants with wild-type KRAS were randomized to FOLFIRI chemotherapy regimen administered in cycles every two weeks.</description>
          </group>
          <group group_id="O3">
            <title>Mutant KRAS - Panitumumab Plus FOLFIRI</title>
            <description>Participants with mutant KRAS were randomized to 6 mg/kg panitumumab plus FOLFIRI chemotherapy regimen administered in cycles every two weeks.</description>
          </group>
          <group group_id="O4">
            <title>Mutant KRAS - FOLFIRI Alone</title>
            <description>Participants with mutant KRAS were randomized to FOLFIRI chemotherapy regimen administered in cycles every two weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Duration of Response</title>
          <description>Calculated only for those participants with an objective response as the time from the first objective response (subsequently confirmed within no less than 4 weeks) to first observed disease progression per modified-RECIST criteria. Participants not meeting these criteria by the analysis data cutoff date were censored at their last evaluable disease assessment date.
Progressive disease is defined as a ≥ 20% increase in the size of target lesions or unequivocal progression of existing non-target lesions or any new lesions.</description>
          <population>KRAS Central Tumor Response Analysis Set: Responders</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="105"/>
                <count group_id="O2" value="28"/>
                <count group_id="O3" value="31"/>
                <count group_id="O4" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.6" lower_limit="6.7" upper_limit="9.4"/>
                    <measurement group_id="O2" value="6.6" lower_limit="5.7" upper_limit="10.4"/>
                    <measurement group_id="O3" value="6.0" lower_limit="5.4" upper_limit="7.4"/>
                    <measurement group_id="O4" value="7.4" lower_limit="4.0" upper_limit="8.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Adverse Events (AEs)</title>
        <description>A serious adverse event (SAE) is defined by regulatory authorities as one that • is fatal • is life threatening (places the subject at immediate risk of death) • requires in-patient hospitalization or prolongation of existing hospitalization • results in persistent or significant disability/incapacity • is a congenital anomaly/birth defect • other significant medical hazard. The relationship of the adverse event to the study treatment was assessed by the Investigator by means of the question: “Is there a reasonable possibility that the event may have been caused by the study treatment?&quot;</description>
        <time_frame>From randomization until the data cut-off date of 30 April 2009. Maximum follow-up time was 33 months.</time_frame>
        <population>Safety analysis set: all participants who received at least 1 dose of panitumumab or chemotherapy. One participant was randomized to Panitumumab Plus FOLFIRI, but received FOLFIRI Alone and is included in the FOLFIRI Alone group for safety analyses.</population>
        <group_list>
          <group group_id="O1">
            <title>Panitumumab Plus FOLFIRI</title>
            <description>Participants received 6 mg/kg panitumumab IV plus a standard chemotherapy regimen (FOLFIRI) consisting of 5-FU, leucovorin and irinotecan. Treatment was administered in cycles every two weeks.</description>
          </group>
          <group group_id="O2">
            <title>FOLFIRI Alone</title>
            <description>Participants received FOLFIRI chemotherapy regimen administered in cycles every two weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Adverse Events (AEs)</title>
          <description>A serious adverse event (SAE) is defined by regulatory authorities as one that • is fatal • is life threatening (places the subject at immediate risk of death) • requires in-patient hospitalization or prolongation of existing hospitalization • results in persistent or significant disability/incapacity • is a congenital anomaly/birth defect • other significant medical hazard. The relationship of the adverse event to the study treatment was assessed by the Investigator by means of the question: “Is there a reasonable possibility that the event may have been caused by the study treatment?&quot;</description>
          <population>Safety analysis set: all participants who received at least 1 dose of panitumumab or chemotherapy. One participant was randomized to Panitumumab Plus FOLFIRI, but received FOLFIRI Alone and is included in the FOLFIRI Alone group for safety analyses.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="587"/>
                <count group_id="O2" value="594"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any adverse event</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="584"/>
                    <measurement group_id="O2" value="573"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serious adverse event</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="232"/>
                    <measurement group_id="O2" value="175"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Leading to discontinuation of any study drug</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="123"/>
                    <measurement group_id="O2" value="64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Treatment-related adverse event (TRAE)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="577"/>
                    <measurement group_id="O2" value="542"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serious treatment-related adverse event</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="124"/>
                    <measurement group_id="O2" value="90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TRAE leading to discontinuation of any study drug</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97"/>
                    <measurement group_id="O2" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>The median treatment period was approximately 6.2 months in the Panitumumab plus FOLFIRI arm, and 4.7 months in the FOLFIRI Alone arm.</time_frame>
      <desc>One participant was randomized to Panitumumab Plus FOLFIRI, but received FOLFIRI Alone and is included in the FOLFIRI Alone group for safety analyses.
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.</desc>
      <group_list>
        <group group_id="E1">
          <title>Panitumumab Plus FOLFIRI</title>
          <description>Participants received 6 mg/kg panitumumab IV plus a standard chemotherapy regimen (FOLFIRI) consisting of 5-FU, leucovorin and irinotecan. Treatment was administered in cycles every two weeks.</description>
        </group>
        <group group_id="E2">
          <title>FOLFIRI Alone</title>
          <description>Participants received FOLFIRI chemotherapy regimen administered in cycles every two weeks.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 12.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="232" subjects_at_risk="587"/>
                <counts group_id="E2" subjects_affected="175" subjects_at_risk="594"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="587"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="594"/>
              </event>
              <event>
                <sub_title>Disseminated intravascular coagulation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="587"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="594"/>
              </event>
              <event>
                <sub_title>Febrile bone marrow aplasia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="587"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="594"/>
              </event>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="587"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="594"/>
              </event>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="587"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="594"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="587"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="594"/>
              </event>
              <event>
                <sub_title>Pancytopenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="587"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="594"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="587"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="594"/>
              </event>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="587"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="594"/>
              </event>
              <event>
                <sub_title>Arrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="587"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="594"/>
              </event>
              <event>
                <sub_title>Arteriospasm coronary</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="587"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="594"/>
              </event>
              <event>
                <sub_title>Bradycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="587"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="594"/>
              </event>
              <event>
                <sub_title>Cardiac arrest</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="587"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="594"/>
              </event>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="587"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="594"/>
              </event>
              <event>
                <sub_title>Cardiac failure acute</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="587"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="594"/>
              </event>
              <event>
                <sub_title>Cardio-respiratory arrest</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="587"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="594"/>
              </event>
              <event>
                <sub_title>Cardiopulmonary failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="587"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="594"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="587"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="594"/>
              </event>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="587"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="594"/>
              </event>
              <event>
                <sub_title>Sinus bradycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="587"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="594"/>
              </event>
              <event>
                <sub_title>Sinus tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="587"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="594"/>
              </event>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="587"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="594"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Aplasia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="587"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="594"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="587"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="594"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Diplopia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="587"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="594"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal discomfort</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="587"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="594"/>
              </event>
              <event>
                <sub_title>Abdominal hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="587"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="594"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="587"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="594"/>
              </event>
              <event>
                <sub_title>Abdominal pain lower</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="587"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="594"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="587"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="594"/>
              </event>
              <event>
                <sub_title>Anal fistula</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="587"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="594"/>
              </event>
              <event>
                <sub_title>Anal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="587"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="594"/>
              </event>
              <event>
                <sub_title>Anal ulcer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="587"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="594"/>
              </event>
              <event>
                <sub_title>Anorectal disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="587"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="594"/>
              </event>
              <event>
                <sub_title>Ascites</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="587"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="594"/>
              </event>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="587"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="594"/>
              </event>
              <event>
                <sub_title>Colonic obstruction</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="587"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="594"/>
              </event>
              <event>
                <sub_title>Colonic stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="587"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="594"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="587"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="594"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="33" subjects_at_risk="587"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="594"/>
              </event>
              <event>
                <sub_title>Duodenal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="587"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="594"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="587"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="594"/>
              </event>
              <event>
                <sub_title>Dysphagia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="587"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="594"/>
              </event>
              <event>
                <sub_title>Enterocolitis haemorrhagic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="587"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="594"/>
              </event>
              <event>
                <sub_title>Faecal vomiting</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="587"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="594"/>
              </event>
              <event>
                <sub_title>Flatulence</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="587"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="594"/>
              </event>
              <event>
                <sub_title>Gastric haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="587"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="594"/>
              </event>
              <event>
                <sub_title>Gastritis haemorrhagic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="587"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="594"/>
              </event>
              <event>
                <sub_title>Gastrointestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="587"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="594"/>
              </event>
              <event>
                <sub_title>Gastrointestinal toxicity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="587"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="594"/>
              </event>
              <event>
                <sub_title>Haematemesis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="587"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="594"/>
              </event>
              <event>
                <sub_title>Haematochezia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="587"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="594"/>
              </event>
              <event>
                <sub_title>Ileal perforation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="587"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="594"/>
              </event>
              <event>
                <sub_title>Ileus</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="587"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="594"/>
              </event>
              <event>
                <sub_title>Intestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="587"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="594"/>
              </event>
              <event>
                <sub_title>Intestinal perforation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="587"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="594"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="587"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="594"/>
              </event>
              <event>
                <sub_title>Neutropenic colitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="587"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="594"/>
              </event>
              <event>
                <sub_title>Oesophagitis ulcerative</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="587"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="594"/>
              </event>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="587"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="594"/>
              </event>
              <event>
                <sub_title>Proctalgia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="587"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="594"/>
              </event>
              <event>
                <sub_title>Proctitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="587"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="594"/>
              </event>
              <event>
                <sub_title>Rectal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="587"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="594"/>
              </event>
              <event>
                <sub_title>Reflux oesophagitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="587"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="594"/>
              </event>
              <event>
                <sub_title>Retroperitoneal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="587"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="594"/>
              </event>
              <event>
                <sub_title>Sigmoiditis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="587"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="594"/>
              </event>
              <event>
                <sub_title>Small intestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="587"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="594"/>
              </event>
              <event>
                <sub_title>Stomatitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="587"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="594"/>
              </event>
              <event>
                <sub_title>Subileus</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="587"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="594"/>
              </event>
              <event>
                <sub_title>Umbilical hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="587"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="594"/>
              </event>
              <event>
                <sub_title>Volvulus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="587"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="594"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="587"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="594"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Accidental death</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="587"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="594"/>
              </event>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="587"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="594"/>
              </event>
              <event>
                <sub_title>Catheter related complication</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="587"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="594"/>
              </event>
              <event>
                <sub_title>Catheter site related reaction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="587"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="594"/>
              </event>
              <event>
                <sub_title>Catheter thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="587"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="594"/>
              </event>
              <event>
                <sub_title>Chest discomfort</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="587"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="594"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="587"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="594"/>
              </event>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="587"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="594"/>
              </event>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="587"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="594"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="587"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="594"/>
              </event>
              <event>
                <sub_title>Gait disturbance</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="587"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="594"/>
              </event>
              <event>
                <sub_title>General physical health deterioration</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="587"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="594"/>
              </event>
              <event>
                <sub_title>Generalised oedema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="587"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="594"/>
              </event>
              <event>
                <sub_title>Hyperthermia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="587"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="594"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="587"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="594"/>
              </event>
              <event>
                <sub_title>Mucosal inflammation</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="587"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="594"/>
              </event>
              <event>
                <sub_title>Multi-organ failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="587"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="594"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="587"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="594"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="587"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="594"/>
              </event>
              <event>
                <sub_title>Performance status decreased</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="587"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="594"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="587"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="594"/>
              </event>
              <event>
                <sub_title>Sudden death</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="587"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="594"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Bile duct obstruction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="587"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="594"/>
              </event>
              <event>
                <sub_title>Biliary colic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="587"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="594"/>
              </event>
              <event>
                <sub_title>Biliary dilatation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="587"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="594"/>
              </event>
              <event>
                <sub_title>Cholangiolitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="587"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="594"/>
              </event>
              <event>
                <sub_title>Cholangitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="587"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="594"/>
              </event>
              <event>
                <sub_title>Cholestasis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="587"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="594"/>
              </event>
              <event>
                <sub_title>Hepatic failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="587"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="594"/>
              </event>
              <event>
                <sub_title>Hyperbilirubinaemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="587"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="594"/>
              </event>
              <event>
                <sub_title>Jaundice</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="587"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="594"/>
              </event>
              <event>
                <sub_title>Jaundice cholestatic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="587"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="594"/>
              </event>
              <event>
                <sub_title>Portal vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="587"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="594"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaphylactic reaction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="587"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="594"/>
              </event>
              <event>
                <sub_title>Drug hypersensitivity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="587"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="594"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Abdominal abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="587"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="594"/>
              </event>
              <event>
                <sub_title>Abdominal infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="587"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="594"/>
              </event>
              <event>
                <sub_title>Abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="587"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="594"/>
              </event>
              <event>
                <sub_title>Actinomycotic pulmonary infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="587"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="594"/>
              </event>
              <event>
                <sub_title>Bacteraemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="587"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="594"/>
              </event>
              <event>
                <sub_title>Biliary sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="587"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="594"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="587"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="594"/>
              </event>
              <event>
                <sub_title>Campylobacter infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="587"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="594"/>
              </event>
              <event>
                <sub_title>Candida sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="587"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="594"/>
              </event>
              <event>
                <sub_title>Candidiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="587"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="594"/>
              </event>
              <event>
                <sub_title>Catheter related infection</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="587"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="594"/>
              </event>
              <event>
                <sub_title>Catheter sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="587"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="594"/>
              </event>
              <event>
                <sub_title>Catheter site infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="587"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="594"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="587"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="594"/>
              </event>
              <event>
                <sub_title>Device related infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="587"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="594"/>
              </event>
              <event>
                <sub_title>Escherichia sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="587"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="594"/>
              </event>
              <event>
                <sub_title>Febrile infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="587"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="594"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="587"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="594"/>
              </event>
              <event>
                <sub_title>Gastroenteritis viral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="587"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="594"/>
              </event>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="587"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="594"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="587"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="594"/>
              </event>
              <event>
                <sub_title>Klebsiella infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="587"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="594"/>
              </event>
              <event>
                <sub_title>Lower respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="587"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="594"/>
              </event>
              <event>
                <sub_title>Neutropenic sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="587"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="594"/>
              </event>
              <event>
                <sub_title>Oropharyngitis fungal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="587"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="594"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="587"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="594"/>
              </event>
              <event>
                <sub_title>Post procedural infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="587"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="594"/>
              </event>
              <event>
                <sub_title>Pyelonephritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="587"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="594"/>
              </event>
              <event>
                <sub_title>Pyelonephritis acute</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="587"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="594"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="587"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="594"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="587"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="594"/>
              </event>
              <event>
                <sub_title>Septic shock</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="587"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="594"/>
              </event>
              <event>
                <sub_title>Staphylococcal infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="587"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="594"/>
              </event>
              <event>
                <sub_title>Staphylococcal sepsis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="587"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="594"/>
              </event>
              <event>
                <sub_title>Subcutaneous abscess</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="587"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="594"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="587"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="594"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="587"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="594"/>
              </event>
              <event>
                <sub_title>Urosepsis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="587"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="594"/>
              </event>
              <event>
                <sub_title>Vaginitis bacterial</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="587"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="594"/>
              </event>
              <event>
                <sub_title>Viral infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="587"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="594"/>
              </event>
              <event>
                <sub_title>Wound infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="587"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="594"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Concussion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="587"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="594"/>
              </event>
              <event>
                <sub_title>Contrast media reaction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="587"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="594"/>
              </event>
              <event>
                <sub_title>Drug administration error</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="587"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="594"/>
              </event>
              <event>
                <sub_title>Femur fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="587"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="594"/>
              </event>
              <event>
                <sub_title>Gastrointestinal stoma complication</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="587"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="594"/>
              </event>
              <event>
                <sub_title>Incisional hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="587"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="594"/>
              </event>
              <event>
                <sub_title>Joint injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="587"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="594"/>
              </event>
              <event>
                <sub_title>Overdose</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="587"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="594"/>
              </event>
              <event>
                <sub_title>Perinephric collection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="587"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="594"/>
              </event>
              <event>
                <sub_title>Post procedural complication</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="587"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="594"/>
              </event>
              <event>
                <sub_title>Post procedural haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="587"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="594"/>
              </event>
              <event>
                <sub_title>Postoperative respiratory distress</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="587"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="594"/>
              </event>
              <event>
                <sub_title>Procedural site reaction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="587"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="594"/>
              </event>
              <event>
                <sub_title>Subdural haematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="587"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="594"/>
              </event>
              <event>
                <sub_title>Subdural haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="587"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="594"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="587"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="594"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="587"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="594"/>
              </event>
              <event>
                <sub_title>Blood creatinine increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="587"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="594"/>
              </event>
              <event>
                <sub_title>General physical condition abnormal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="587"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="594"/>
              </event>
              <event>
                <sub_title>Haemoglobin decreased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="587"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="594"/>
              </event>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="587"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="594"/>
              </event>
              <event>
                <sub_title>White blood cell count decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="587"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="594"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="587"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="594"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="587"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="594"/>
              </event>
              <event>
                <sub_title>Diabetes mellitus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="587"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="594"/>
              </event>
              <event>
                <sub_title>Failure to thrive</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="587"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="594"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="587"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="594"/>
              </event>
              <event>
                <sub_title>Hyperkalaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="587"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="594"/>
              </event>
              <event>
                <sub_title>Hypocalcaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="587"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="594"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="587"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="594"/>
              </event>
              <event>
                <sub_title>Hypomagnesaemia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="587"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="594"/>
              </event>
              <event>
                <sub_title>Hypoproteinaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="587"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="594"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="587"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="594"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="587"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="594"/>
              </event>
              <event>
                <sub_title>Bone pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="587"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="594"/>
              </event>
              <event>
                <sub_title>Flank pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="587"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="594"/>
              </event>
              <event>
                <sub_title>Groin pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="587"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="594"/>
              </event>
              <event>
                <sub_title>Hip swelling</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="587"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="594"/>
              </event>
              <event>
                <sub_title>Muscle atrophy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="587"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="594"/>
              </event>
              <event>
                <sub_title>Muscular weakness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="587"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="594"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="587"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="594"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="587"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="594"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Bronchial carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="587"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="594"/>
              </event>
              <event>
                <sub_title>Colon cancer metastatic</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="587"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="594"/>
              </event>
              <event>
                <sub_title>Colorectal cancer metastatic</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="587"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="594"/>
              </event>
              <event>
                <sub_title>Gastrointestinal cancer metastatic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="587"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="594"/>
              </event>
              <event>
                <sub_title>Malignant ascites</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="587"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="594"/>
              </event>
              <event>
                <sub_title>Malignant neoplasm progression</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="587"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="594"/>
              </event>
              <event>
                <sub_title>Malignant peritoneal neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="587"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="594"/>
              </event>
              <event>
                <sub_title>Metastases to bone</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="587"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="594"/>
              </event>
              <event>
                <sub_title>Metastases to central nervous system</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="587"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="594"/>
              </event>
              <event>
                <sub_title>Metastases to liver</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="587"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="594"/>
              </event>
              <event>
                <sub_title>Metastatic neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="587"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="594"/>
              </event>
              <event>
                <sub_title>Tumour associated fever</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="587"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="594"/>
              </event>
              <event>
                <sub_title>Tumour haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="587"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="594"/>
              </event>
              <event>
                <sub_title>Tumour local invasion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="587"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="594"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Ataxia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="587"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="594"/>
              </event>
              <event>
                <sub_title>Brain oedema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="587"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="594"/>
              </event>
              <event>
                <sub_title>Cerebral haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="587"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="594"/>
              </event>
              <event>
                <sub_title>Cerebral infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="587"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="594"/>
              </event>
              <event>
                <sub_title>Cerebral ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="587"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="594"/>
              </event>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="587"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="594"/>
              </event>
              <event>
                <sub_title>Cerebrovascular insufficiency</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="587"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="594"/>
              </event>
              <event>
                <sub_title>Cholinergic syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="587"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="594"/>
              </event>
              <event>
                <sub_title>Chorea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="587"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="594"/>
              </event>
              <event>
                <sub_title>Coma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="587"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="594"/>
              </event>
              <event>
                <sub_title>Depressed level of consciousness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="587"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="594"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="587"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="594"/>
              </event>
              <event>
                <sub_title>Epiduritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="587"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="594"/>
              </event>
              <event>
                <sub_title>Epilepsy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="587"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="594"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="587"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="594"/>
              </event>
              <event>
                <sub_title>Hemiplegia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="587"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="594"/>
              </event>
              <event>
                <sub_title>Lethargy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="587"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="594"/>
              </event>
              <event>
                <sub_title>Loss of consciousness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="587"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="594"/>
              </event>
              <event>
                <sub_title>Nervous system disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="587"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="594"/>
              </event>
              <event>
                <sub_title>Partial seizures</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="587"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="594"/>
              </event>
              <event>
                <sub_title>Sciatica</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="587"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="594"/>
              </event>
              <event>
                <sub_title>Spinal cord compression</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="587"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="594"/>
              </event>
              <event>
                <sub_title>Status epilepticus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="587"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="594"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="587"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="594"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="587"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="594"/>
              </event>
              <event>
                <sub_title>Confusional state</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="587"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="594"/>
              </event>
              <event>
                <sub_title>Mental status changes</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="587"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="594"/>
              </event>
              <event>
                <sub_title>Mood altered</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="587"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="594"/>
              </event>
              <event>
                <sub_title>Panic attack</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="587"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="594"/>
              </event>
              <event>
                <sub_title>Psychotic disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="587"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="594"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Dysuria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="587"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="594"/>
              </event>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="587"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="594"/>
              </event>
              <event>
                <sub_title>Hydronephrosis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="587"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="594"/>
              </event>
              <event>
                <sub_title>Renal colic</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="587"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="594"/>
              </event>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="587"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="594"/>
              </event>
              <event>
                <sub_title>Renal failure acute</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="587"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="594"/>
              </event>
              <event>
                <sub_title>Ureteric obstruction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="587"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="594"/>
              </event>
              <event>
                <sub_title>Urinary retention</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="587"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="594"/>
              </event>
              <event>
                <sub_title>Urinary tract obstruction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="587"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="594"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Genital ulceration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="587"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="594"/>
              </event>
              <event>
                <sub_title>Pelvic pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="587"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="594"/>
              </event>
              <event>
                <sub_title>Perineal fistula</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="587"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="594"/>
              </event>
              <event>
                <sub_title>Vulvovaginal pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="587"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="594"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dysphonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="587"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="594"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="587"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="594"/>
              </event>
              <event>
                <sub_title>Dyspnoea exertional</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="587"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="594"/>
              </event>
              <event>
                <sub_title>Haemoptysis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="587"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="594"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="587"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="594"/>
              </event>
              <event>
                <sub_title>Interstitial lung disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="587"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="594"/>
              </event>
              <event>
                <sub_title>Lung disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="587"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="594"/>
              </event>
              <event>
                <sub_title>Lung infiltration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="587"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="594"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="587"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="594"/>
              </event>
              <event>
                <sub_title>Pneumonitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="587"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="594"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="587"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="594"/>
              </event>
              <event>
                <sub_title>Productive cough</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="587"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="594"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="587"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="594"/>
              </event>
              <event>
                <sub_title>Respiratory distress</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="587"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="594"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="587"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="594"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Angioedema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="587"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="594"/>
              </event>
              <event>
                <sub_title>Dermal cyst</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="587"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="594"/>
              </event>
              <event>
                <sub_title>Dermatitis acneiform</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="587"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="594"/>
              </event>
              <event>
                <sub_title>Dermatitis contact</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="587"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="594"/>
              </event>
              <event>
                <sub_title>Erythema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="587"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="594"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="587"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="594"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="587"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="594"/>
              </event>
              <event>
                <sub_title>Skin exfoliation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="587"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="594"/>
              </event>
              <event>
                <sub_title>Skin toxicity</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="587"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="594"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Liver operation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="587"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="594"/>
              </event>
              <event>
                <sub_title>Stent placement</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="587"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="594"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Aortic aneurysm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="587"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="594"/>
              </event>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="587"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="594"/>
              </event>
              <event>
                <sub_title>Embolism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="587"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="594"/>
              </event>
              <event>
                <sub_title>Embolism venous</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="587"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="594"/>
              </event>
              <event>
                <sub_title>Haematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="587"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="594"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="587"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="594"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="587"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="594"/>
              </event>
              <event>
                <sub_title>Orthostatic hypotension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="587"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="594"/>
              </event>
              <event>
                <sub_title>Pelvic venous thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="587"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="594"/>
              </event>
              <event>
                <sub_title>Thrombophlebitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="587"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="594"/>
              </event>
              <event>
                <sub_title>Thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="587"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="594"/>
              </event>
              <event>
                <sub_title>Vena cava thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="587"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="594"/>
              </event>
              <event>
                <sub_title>Venous thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="587"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="594"/>
              </event>
              <event>
                <sub_title>Venous thrombosis limb</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="587"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="594"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 12.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="575" subjects_at_risk="587"/>
                <counts group_id="E2" subjects_affected="546" subjects_at_risk="594"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="79" subjects_at_risk="587"/>
                <counts group_id="E2" subjects_affected="110" subjects_at_risk="594"/>
              </event>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" subjects_affected="64" subjects_at_risk="587"/>
                <counts group_id="E2" subjects_affected="60" subjects_at_risk="594"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="207" subjects_at_risk="587"/>
                <counts group_id="E2" subjects_affected="209" subjects_at_risk="594"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="587"/>
                <counts group_id="E2" subjects_affected="39" subjects_at_risk="594"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Conjunctivitis</sub_title>
                <counts group_id="E1" subjects_affected="81" subjects_at_risk="587"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="594"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="122" subjects_at_risk="587"/>
                <counts group_id="E2" subjects_affected="105" subjects_at_risk="594"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="37" subjects_at_risk="587"/>
                <counts group_id="E2" subjects_affected="33" subjects_at_risk="594"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="139" subjects_at_risk="587"/>
                <counts group_id="E2" subjects_affected="125" subjects_at_risk="594"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="372" subjects_at_risk="587"/>
                <counts group_id="E2" subjects_affected="321" subjects_at_risk="594"/>
              </event>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="587"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="594"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="40" subjects_at_risk="587"/>
                <counts group_id="E2" subjects_affected="32" subjects_at_risk="594"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="276" subjects_at_risk="587"/>
                <counts group_id="E2" subjects_affected="269" subjects_at_risk="594"/>
              </event>
              <event>
                <sub_title>Stomatitis</sub_title>
                <counts group_id="E1" subjects_affected="131" subjects_at_risk="587"/>
                <counts group_id="E2" subjects_affected="75" subjects_at_risk="594"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="154" subjects_at_risk="587"/>
                <counts group_id="E2" subjects_affected="162" subjects_at_risk="594"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="74" subjects_at_risk="587"/>
                <counts group_id="E2" subjects_affected="81" subjects_at_risk="594"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="203" subjects_at_risk="587"/>
                <counts group_id="E2" subjects_affected="186" subjects_at_risk="594"/>
              </event>
              <event>
                <sub_title>Mucosal inflammation</sub_title>
                <counts group_id="E1" subjects_affected="121" subjects_at_risk="587"/>
                <counts group_id="E2" subjects_affected="68" subjects_at_risk="594"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="59" subjects_at_risk="587"/>
                <counts group_id="E2" subjects_affected="41" subjects_at_risk="594"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="43" subjects_at_risk="587"/>
                <counts group_id="E2" subjects_affected="29" subjects_at_risk="594"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="105" subjects_at_risk="587"/>
                <counts group_id="E2" subjects_affected="89" subjects_at_risk="594"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Paronychia</sub_title>
                <counts group_id="E1" subjects_affected="102" subjects_at_risk="587"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="594"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" subjects_affected="60" subjects_at_risk="587"/>
                <counts group_id="E2" subjects_affected="29" subjects_at_risk="594"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" subjects_affected="146" subjects_at_risk="587"/>
                <counts group_id="E2" subjects_affected="93" subjects_at_risk="594"/>
              </event>
              <event>
                <sub_title>Hypocalcaemia</sub_title>
                <counts group_id="E1" subjects_affected="32" subjects_at_risk="587"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="594"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" subjects_affected="65" subjects_at_risk="587"/>
                <counts group_id="E2" subjects_affected="27" subjects_at_risk="594"/>
              </event>
              <event>
                <sub_title>Hypomagnesaemia</sub_title>
                <counts group_id="E1" subjects_affected="120" subjects_at_risk="587"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="594"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="62" subjects_at_risk="587"/>
                <counts group_id="E2" subjects_affected="44" subjects_at_risk="594"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="36" subjects_at_risk="587"/>
                <counts group_id="E2" subjects_affected="35" subjects_at_risk="594"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="34" subjects_at_risk="587"/>
                <counts group_id="E2" subjects_affected="40" subjects_at_risk="594"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="53" subjects_at_risk="587"/>
                <counts group_id="E2" subjects_affected="48" subjects_at_risk="594"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="42" subjects_at_risk="587"/>
                <counts group_id="E2" subjects_affected="55" subjects_at_risk="594"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="54" subjects_at_risk="587"/>
                <counts group_id="E2" subjects_affected="36" subjects_at_risk="594"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" subjects_affected="52" subjects_at_risk="587"/>
                <counts group_id="E2" subjects_affected="38" subjects_at_risk="594"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Acne</sub_title>
                <counts group_id="E1" subjects_affected="80" subjects_at_risk="587"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="594"/>
              </event>
              <event>
                <sub_title>Alopecia</sub_title>
                <counts group_id="E1" subjects_affected="124" subjects_at_risk="587"/>
                <counts group_id="E2" subjects_affected="136" subjects_at_risk="594"/>
              </event>
              <event>
                <sub_title>Dermatitis acneiform</sub_title>
                <counts group_id="E1" subjects_affected="141" subjects_at_risk="587"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="594"/>
              </event>
              <event>
                <sub_title>Dry skin</sub_title>
                <counts group_id="E1" subjects_affected="129" subjects_at_risk="587"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="594"/>
              </event>
              <event>
                <sub_title>Erythema</sub_title>
                <counts group_id="E1" subjects_affected="92" subjects_at_risk="587"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="594"/>
              </event>
              <event>
                <sub_title>Nail disorder</sub_title>
                <counts group_id="E1" subjects_affected="43" subjects_at_risk="587"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="594"/>
              </event>
              <event>
                <sub_title>Palmar-plantar erythrodysaesthesia syndrome</sub_title>
                <counts group_id="E1" subjects_affected="54" subjects_at_risk="587"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="594"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="107" subjects_at_risk="587"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="594"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="330" subjects_at_risk="587"/>
                <counts group_id="E2" subjects_affected="38" subjects_at_risk="594"/>
              </event>
              <event>
                <sub_title>Skin fissures</sub_title>
                <counts group_id="E1" subjects_affected="94" subjects_at_risk="587"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="594"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results aftercompletion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Study Director</name_or_title>
      <organization>Amgen Inc.</organization>
      <phone>866-572-6436</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

